Diabetes Market in Japan: Key Research Findings 2020
Yano Research Institute (the President, Takashi Mizukoshi) carried out a survey on the domestic diabetes market and found out the current status of appliances for diabetes testing and diagnosis, and drugs, the trend of market players, and the future outlook.
The diabetes market in this research refers to the market of appliances for diabetes testing and diagnosis (blood glucose meter and related products, urine glucose meter and related products) and drugs (antidiabetic drugs and drugs for complications). The diabetes market size (total value of the markets of diabetes testing/diagnosis appliances and drugs) for FY2019 was estimated as 652,440 million yen.
The market of appliances for diabetes testing and diagnosis has been on the decline in recent years, partly because of fiercer price competition of SMBG (Self-Monitoring of Blood Glucose). As hypoglycemic agent such as DPP4 inhibitor has begun widely in use, growing number of patients has determined not to choose insulin therapies or has succeeded in avoiding insulin therapies, which slashed the demand for glucose meters furthermore. Although the number of domestic diabetes patients increasing, the above reasons continue the market of appliances for diabetes testing and diagnosis to shrink.
The diabetes drugs market size is on the rise, due to growth in DPP4 inhibitors, SGLT2 inhibitors, and recently-emerged combination drugs. In particular, the category of SGLT2 inhibitors, which has not yet been permeated in Japan, is expanding.
Diabetes Testing/Diagnosis Appliances Market Proceeds to Next Competition Stage, with CGM (Continuous Glucose Monitoring) Attracting Attention for Being Added in NHI Point Items, SMBG Development Being Matured
The trends of CGM (Continuous Glucose Monitoring) and SMBG (Self-Monitoring of Blood Glucose) are attracting attention.
In April 2020, new remuneration was set for SMBG, while NHI points were newly added for CGM. Having attracted attention since its release in Japan, CGM is likely to show higher profile.
On the contrary, the race among the manufacturers for developing SMBG has entered a maturity phase. The functional or technological development of SMBG has been overall done with, which led the manufacturers to enter new competition stage, differentiating with each other by appealing the packaging designs and user-friendliness.
The diabetes market size (total value of the diabetes testing/diagnosis appliances and drugs markets) for FY2019 is projected to generate 668,720 million yen.
The diabetes testing/diagnosis appliances market is likely to show continuous decline due to decreased demand stemming from price competition of SMBG and decreased prescriptions of insulin. The significant impact to the market hereafter, if any, can be innovative products such as noninvasive glucose monitoring devices, or changes in the systems such as newly established remuneration regarding self-monitoring of blood glucose.
The diabetes drugs market is on the rise, driven by DPP4 inhibitors and SGLT2 inhibitors. However, when considering cheaper generic drugs being in wider use due to patent expiration of the original drug, and decreasing new drug candidates for anti-diabetes drugs at each pharmaceutical company, the market is projected to downturn within the next 5 years.
In addition, the common issue shared between the markets of diabetes appliances and drugs is the system to provide information and to encourage the sales. As the conventional face-to-face sales activities are restricted due to COVID-19 pandemics, availability of online tools to achieve efficiency in both sales activities and information provision is highly likely to determine the sales performance at enterprises.
The copyright and all other rights pertaining to this report belong to Yano Research Institute.
Please contact our PR team when quoting the report contents for the purpose other than media coverage.
Depending on the purpose of using our report, we may ask you to present your sentences for confirmation beforehand.